

EUROPEAN UNION COULD SAVE 27€ BILLION A YEAR WITH FAIRER MEDICINE PRICES

What AIM's Fair Pricing Calculator Shows
Across 10 Medicines in 6 European
Countries



6,2€
billion

potential annual
net savings across
participating
countries



73%

reduced spending
on medicines



Up to
97%
lower

than current
list prices



Base-case fair prices assume €800 million in R&D costs per medicine and are compared with 2020 list prices and estimated net prices, where available, across six countries to estimate savings.



PER-COUNTRY OUTCOME

Country	Gross reduction (vs.list price)	Net reduction (vs.net price)
Germany	77%	74%
Belgium	81%	71%
Estonia	59%	37%
Netherlands	72%	69%
Switzerland	78%	NA
Slovenia	48%	NA

Average reduction in medicine spending across the 10 medicines studied: 77% gross / 73% net.

Extrapolated from 6 countries (gross) and 4 countries (net) to the EU27: €38bn gross / €27bn net.

WHAT IS THE AIM OF THE FAIR PRICING CALCULATOR?

The goal

To estimate a fair medicine price using transparent cost and value inputs.

What it includes

R&D, production, sales and information costs, profit, therapeutic value, and patient population.

What it gives

A European fair price, with country adjustment by purchasing power.


















AIM Healthcare and social benefits for all
















LARGE PRICING GAPS IN CANCER AND CHRONIC TREATMENTS

Six medicines across cancer and chronic conditions illustrate how large the gap can be between fair prices and current prices

Cancer medicines

Medicine	Percentage lower
 Darzalex[®]	83% lower
 Fair price / month	2,384€
 Median list price / month	14,247€
 Treatment	5 months
 Savings per patient	59,315€
 Ibrance[®]	87% lower
 Fair price / month	304€
 Median list price / month	2,372€
 Treatment	9 months
 Savings per patient	18,61€
 Lonsurf[®]	22% lower
 Fair price / month	1,900€
 Median list price / month	2,446€
 Treatment	2 months
 Savings per patient	1,092€

Chronic treatments

 Triumeq[®] (HIV)	90% lower
 Fair price / month	79€
 Median list price / month	797€
 Treatment	10 years
 Savings per patient	86,160€
 Ocrevus[®] (Multiple Sclerosis)	89% lower
 Fair price / month	188€
 Median list price / month	1,708€
 Treatment	10 years
 Savings per patient	182,400€
 Maviret[®] (Hepatitis C)	81% lower
 Fair price / month	2,428€
 Median list price / month	12,633€
 Treatment	2 months
 Savings per patient	20,410€



CURRENT USE

Dutch health insurers already use the calculator in price negotiations with pharmaceutical companies. The model could also support hospital tender negotiations.



FUTURE USE

The AIM calculator is being further developed into the Horizon Europe-funded ASCERTAIN project to help decision-makers assess prices and value more transparently.

“Fair pricing can strengthen negotiations, improve transparency, and protect the sustainability of European health systems.”